A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis-Reference-Cited by-同舟云学术

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

Published:2020-07 Issue:1 Volume:73 Page:94-101
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Kowdley Kris V.,Vuppalanchi Raj,Levy Cynthia,Floreani Annarosa,Andreone Pietro,LaRusso Nicholas F.,Shrestha Roshan,Trotter James,Goldberg David,Rushbrook Simon,Hirschfield Gideon M.,Schiano Thomas,Jin Yuying,Pencek Richard,MacConell Leigh,Shapiro David,Bowlus Christopher L.

Funder

Intercept Pharmaceuticals, Inc

Publisher

Elsevier BV

Subject

Hepatology

Reference20 articles.

1. Primary sclerosing cholangitis - a comprehensive review;Karlsen;J Hepatol,2017

2. Primary sclerosing cholangitis;Lazaridis;N Engl J Med,2016

3. ACG clinical guideline: primary sclerosing cholangitis;Lindor;Am J Gastroenterol,2015

4. Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system;Goode;Hepatology,2019

5. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis;Al Mamari;J Hepatol,2013

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis;Journal of Controlled Release;2024-10

2. GSK805 inhibits alpha‐smooth muscle expression and modulates liver inflammation without impairing the well‐being of mice;The FASEB Journal;2024-08-19

3. Total astragalus saponins attenuate primary sclerosing cholangitis in mice by upregulation of TGR5;Phytotherapy Research;2024-07-20

4. The gut microbiota-bile acid axis in cholestatic liver disease;Molecular Medicine;2024-07-19

5. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials;Expert Opinion on Emerging Drugs;2024-07-04